AbCellera Biologics Inc. Proceeds from Sale and Maturity of Marketable Securities
AbCellera Biologics Inc. (ABCL) reported Proceeds from Sale and Maturity of Marketable Securities of $293.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-05
- AbCellera Biologics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $149.75M, a 32.05% increase year-over-year.
- AbCellera Biologics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $143.80M, a 24.33% decline year-over-year.
- AbCellera Biologics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $119.54M, a 40.79% decline year-over-year.
- AbCellera Biologics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $83.10M, a 57.73% decline year-over-year.
- AbCellera Biologics Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $506.07M, a 46.04% decline from fiscal 2024.
- AbCellera Biologics Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $937.88M, a 2.96% increase from fiscal 2023.
- AbCellera Biologics Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $910.94M, a 78.39% increase from fiscal 2022.
- AbCellera Biologics Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $510.63M, a 1749.58% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $149.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $293.56M 10-Q · filed 2026-08-05 | $413.09M derived: sum of 3 quarters · filed 2026-08-05 | $496.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $143.80M 10-Q · filed 2026-05-11 | $263.34M derived: sum of 2 quarters · filed 2026-05-11 | $346.44M derived: sum of 3 quarters · filed 2026-05-11 | $459.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $119.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $202.63M derived: sum of 2 quarters · filed 2026-02-24 | $316.05M derived: sum of 3 quarters · filed 2026-08-05 | $506.07M 10-K · filed 2026-02-24 |
| 2025-09-30 | $83.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $196.51M derived: sum of 2 quarters · filed 2026-08-05 | $386.54M 10-Q · filed 2025-11-06 | $588.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $113.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $303.44M 10-Q · filed 2026-08-05 | $505.33M derived: sum of 3 quarters · filed 2026-08-05 | $701.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $190.03M 10-Q · filed 2026-05-11 | $391.92M derived: sum of 2 quarters · filed 2026-05-11 | $588.52M derived: sum of 3 quarters · filed 2026-05-11 | $821.36M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $201.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $398.50M derived: sum of 2 quarters · filed 2026-02-24 | $631.34M derived: sum of 3 quarters · filed 2026-02-24 | $937.88M 10-K · filed 2026-02-24 |
| 2024-09-30 | $196.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $429.44M derived: sum of 2 quarters · filed 2025-11-06 | $735.99M 10-Q · filed 2025-11-06 | $1.00B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $232.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $539.38M 10-Q · filed 2025-08-07 | $807.41M derived: sum of 3 quarters · filed 2026-02-24 | $1.03B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $306.55M 10-Q · filed 2025-05-08 | $574.57M derived: sum of 2 quarters · filed 2026-02-24 | $794.67M derived: sum of 3 quarters · filed 2026-02-24 | $954.84M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $268.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $488.12M derived: sum of 2 quarters · filed 2026-02-24 | $648.30M derived: sum of 3 quarters · filed 2026-02-24 | $910.94M 10-K · filed 2026-02-24 |
| 2023-09-30 | $220.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $380.27M derived: sum of 2 quarters · filed 2024-11-04 | $642.91M 10-Q · filed 2024-11-04 | $735.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $160.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $422.81M 10-Q · filed 2024-08-06 | $515.21M derived: sum of 3 quarters · filed 2025-02-27 | $787.64M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $262.64M 10-Q · filed 2024-05-07 | $355.03M derived: sum of 2 quarters · filed 2025-02-27 | $627.46M derived: sum of 3 quarters · filed 2025-02-27 | $715.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $92.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $364.82M derived: sum of 2 quarters · filed 2025-02-27 | $453.34M derived: sum of 3 quarters · filed 2025-02-27 | $510.63M 10-K · filed 2025-02-27 |
| 2022-09-30 | $272.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $360.94M derived: sum of 2 quarters · filed 2023-11-02 | $418.24M 10-Q · filed 2023-11-02 | $436.32M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $88.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $145.81M 10-Q · filed 2023-08-03 | $163.89M derived: sum of 3 quarters · filed 2024-02-20 | |
| 2022-03-31 | $57.29M 10-Q · filed 2023-05-04 | $75.38M derived: sum of 2 quarters · filed 2024-02-20 | ||
| 2021-12-31 | $18.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $27.61M 10-K · filed 2024-02-20 | ||
| 2021-09-30 | $9.53M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |